BioHarvest Sciences latest financial numbers shows continued growth for flagship product VINIA

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share significant achievements from the company's second-quarter results.

Sobel highlighted key performance indicators that demonstrate BioHarvest's robust growth and strategic advancements. A standout achievement was the remarkable growth in revenue generated by the company's flagship product, VINIA.

BioHarvest Sciences achieved $2.75 million in revenue from VINIA in 2Q 2023, marking an impressive 228% increase compared to the same quarter of the previous year. This revenue figure also represents a 27% growth compared to the previous quarter, Q1 2023. The strong revenue growth showcases the increasing demand and market acceptance of the VINIA product.

Sobel emphasized the significant improvement in gross product margins for the quarter. The gross product margin increased to 40%, a substantial jump from 12% in Q2 2022. This improvement is attributed to scaling production and achieving operational efficiencies.

BioHarvest Sciences anticipates that these margins will continue to rise as production continues to expand.

The company's recurring revenue model was highlighted as a key driver of its success. Sobel discussed the growth in both new customers and total subscribers, demonstrating the power of this model to accelerate revenue growth and contribute to achieving profitability. Notably, the total active VINIA subscribers increased by a remarkable 620% compared to Q2 2022, showcasing the growing interest and adoption of the product.

Contact Details

Proactive Investors Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com